Emtricitabine/tenofovir disoproxil fumarate: A review of its use in HIV-1 pre-exposure prophylaxis

Drugs

Volumn 73, Issue 3, 2013, Pages 279-291

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; CIDOFOVIR; CREATININE; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; PHOSPHATE; PLACEBO; TENOFOVIR DISOPROXIL;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; AREA UNDER THE CURVE; BIOEQUIVALENCE; BONE DENSITY; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIZZINESS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENTIATION; DRUG TOLERABILITY; FATIGUE; FRACTURE; GASTROINTESTINAL SYMPTOM; GENITAL ULCER; HEADACHE; HEPATITIS B; HEPATOMEGALY; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGH RISK BEHAVIOR; HIGH RISK POPULATION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; KIDNEY CLEARANCE; KIDNEY DISEASE; KIDNEY FUNCTION; LACTIC ACIDOSIS; MALE HOMOSEXUAL; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY (TOPIC); NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; REVIEW; RISK REDUCTION; SAFE SEX; SEROCONVERSION; SEXUAL BEHAVIOR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; SIMIAN IMMUNODEFICIENCY VIRUS; STEATOSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS MUTATION; VOMITING; WEIGHT REDUCTION;

ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; ORGANOPHOSPHONATES; PATIENT ACCEPTANCE OF HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAFE SEX; SEXUAL BEHAVIOR; SEXUALITY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84877116842     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0024-4     Document Type: Review

References (64)

1. UNAIDS Report on the Global AIDS Epidemic: 2012. 2012. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/ gr2012/20121120-AUAIDS-Global-Report-2012-en.pdf. Accessed 4 Dec 2012.
2. Katsidzira L, Hakim JG. HIV prevention in southern Africa: why we must reassess our strategies? Trop Med Int Health. 2011;16(9):1120-30.
3. van Griensven F, de Lind van Wijngaarden JW, Baral S, et al. The global epidemic of HIV infection among men who have sex with men. Curr Opin HIV AIDS. 2009;4(4):300-7.
4. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-9.
5. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006-2009. PLoS ONE. 2011;6(8):e17502.
6. HIV-2 infection surveillance: United States, 1987-2009. MMWR. 2011;60(29):985-8.
7. Krakower D, Mayer KH. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review. Ann Intern Med. 2012;157(7):490-7.
8. Padian NS, McCoy SI, Karim SS, et al. HIV prevention transformed: the new prevention research agenda. Lancet. 2011;378(9787):269-78.
9. Marrazzo JM, Cates W. Interventions to prevent sexually transmitted infections, including HIV infection. Clin Infect Dis. 2011;53(Suppl. 3):S64-78.
10. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2012. http://www.aidsinfo.nih.gov/ guidelines. Accessed 10 Dec 2012.
11. US prescribing information for Truvada (emtricitabine/tenofovir disoproxil fumarate) tablets, for oral use. 2012. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/021752s031lbl.pdf. Accessed 16 Oct 2012.
12. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR. 2011;60(3):65-8.
13. McCormack S, Fidler S, Fisher M, et al. The British HIV Association/British Association for Sexual Health and HIV position statement on pre-exposure prophylaxis in the UK. Int J STD AIDS. 2012;23(1):1-4.
14. Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals [Update of Cochrane Database Syst Rev. 2009;(1):CD007189; PMID: 19160329]. Cochrane Database Syst Rev. 2012;7:CD007189.
15. Centers for Disease Control and Prevention. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR. 2012;61:586-9.
16. Cohen MS, Baden LR. Preexposure prophylaxis for HIV - where do we go from here? N Engl J Med. 2012;367(5):459-61.
17. Karim SSA. Preexposure prophylaxis for HIV prevention: recommend initiating PrEP. N Engl J Med. 2012;367:462-5.
18. Gray GE, Martinson N. Preexposure prophylaxis for HIV prevention: do not recommend initiating PrEP. N Engl J Med. 2012;367:462-5.
19. Colbert JA. Preexposure prophylaxis for HIV prevention: polling results. N Engl J Med. 2012;367:e22.
20. Feinberg J. Truvada PrEP: why I voted "yes". Ann Intern Med. 2012;157(7):521-2.
21. Wood LV, Why I. voted "no" to Truvada PrEP. Ann Intern Med. 2012;157(7):519-20.
22. Perry CM. Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. Drugs. 2009;69(7):843-57.
23. Kearney BP, Flaherty JF, Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin Pharmacokinet. 2004;43(9):595-612.
24. Frampton JE, Perry CM. Emtricitabine: a review of its use in the management of HIV infection. Drugs. 2005;65(10):1427-48.
25. Chapman T, McGavin J, Noble S. Tenofovir disoproxil fumarate. Drugs. 2003;63(15):1597-608.
26. Anderson PL, Kiser JJ, Gardner EM, et al. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011;66(2):240-50.
27. Tsai CC, Follis KE, Sabo A, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995;270(5239):1197-9.
28. Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis. 2006;194(7):904-11.
29. Van Rompay KK, Kearney BP, Sexton JJ, et al. Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr. 2006;43(1):6-14.
30. Van Rompay KK, Miller MD, Marthas ML, et al. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA. J Virol. 2000;74(4):1767-74.
31. Van Rompay KK, McChesney MB, Aguirre NL, et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis. 2001;184(4):429-38.
32. Van Rompay KK, Berardi CJ, Aguirre NL, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS. 1998;12(9):F79-83.
33. Garcia-Lerma JG, Otten RA, Qari SH, et al. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008;5(2):e28.
34. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2(14):14ra4.
35. Cong ME, Youngpairoj AS, Zheng Q, et al. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J Virol. 2011;85(15):7933-6.
36. Denton PW, Estes JD, Sun Z, et al. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008;5(1):e16.
37. Denton PW, Krisko JF, Powell DA, et al. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PLoS ONE. 2010;5(1):e8829.
38. Stoddart CA, Nault G, Galkina SA, et al. Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice. Antimicrob Agents Chemother. 2012;56(4):2162-5.
39. Blum MR, Chittick GE, Begley JA, et al. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol. 2007;47(6):751-9.
40. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS. 2011;25(2):63-71.
41. de Lastours V, Fonsart J, Burlacu R, et al. Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition. Antimicrob Agents Chemother. 2011;55(10):4905-7.
42. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med. 2011;3(112):112re4.
43. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
44. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-99.
45. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-34.
46. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-22.
47. Donnell D, Baeten J, Hendrix C, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda [abstract no. 30]. 19th Conference on Retroviruses and Opportunistic Infections, Seattle (WA); 5-8 Mar 2012.
48. Botswana CSO. Stats brief: preliminary results Botswana AIDS impact survey III (BAIS III), 2008. 2009. http://www.bbca.org.bw/ BAIS%20III%20Stats%20Brief.pdf. Accessed 23 Nov 2012.
49. NIH modifies 'VOICE' HIV prevention study in women. 2011. http://www.nih.gov/news/health/sep2011/niaid-28.htm. Accessed 17 Oct 2012.
50. Q&A: the VOICE HIV prevention study. 2011. http://www.niaid.nih.gov/ news/qa/pages/voiceqa.aspx. Accessed 17 Oct 2012.
51. Mulligan K, Glidden DV, Gonzales P, et al. Effects of FTC/TDF on bone mineral density in seronegative men from 4 continents: DEXA results of the global iPrEx study [abstract no. 94LB]. 18th Conference on Retroviruses and Opportunistic Infections, Boston (MA); 27 Feb-2 Mar 2011.
52. Steinbrook R. Preexposure prophylaxis for HIV infection. JAMA. 2012;308(9):865-6.
53. Jay JS, Gostin LO. Ethical challenges of preexposure prophylaxis for HIV. JAMA. 2012;308(9):867-8.
54. Karim SSA, Karim QA. Antiretroviral prophylaxis for HIV prevention reaches a key milestone. Lancet. 2012;379(9831):2047-8.
55. Hurt CB, Eron JJ Jr. Cohen MS (2011) Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis. 2011;53(12):1265-70.
56. van der Straten A, Van Damme L, Haberer JE, et al. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13-9.
57. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168-74.
58. Truvada Medication Assistance Program: Gilead. 2012. http://www.gilead. com/truvada-assistance-program. Accessed 6 Dec 2012.
59. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48(6):806-15.
60. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS. 2008;22(14):1829-39.
61. Juusola JL, Brandeau ML, Owens DK, et al. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann Intern Med. 2012;156(8):541-50.
62. van de Vijver DAMC, Boucher CAB. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. Curr Opin Infect Dis. 2010;23(6):621-7.
63. Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 2011;8(11):e1001123.
64. Truvada for a pre-exposure prophylaxis (PrEP) indication - official REMS site. 2012. https://www.truvadapreprems.com/. Accessed 6 Dec 2012.